Core Viewpoint - The stock of Yidu Tech (02158) has seen a significant increase, rising over 14% in late trading, with a current price of HKD 6.57 and a trading volume of HKD 466 million [1] Group 1: Company Developments - Yidu Tech's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] - On September 16, during the 2025 Tencent Digital Ecosystem Conference's medical session, Yidu Tech's Senior Solutions Expert Shi Chengfa delivered a speech titled "AI Empowering the Full Process of Clinical Trials," discussing how AI can enhance the efficiency and quality of clinical trials, thereby promoting high-quality development in the industry [1]

Group 1 - The core point of the article is that Yidu Technology (02158) experienced a significant stock price increase, rising over 14% in late trading, with a current price of HKD 6.57 and a trading volume of HKD 466 million [1] - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] - On September 16, during the 2025 Tencent Digital Ecosystem Conference's medical session, Yidu Technology's Senior Solutions Expert Shi Chengfa delivered a speech on "AI Empowering the Full Process of Clinical Trials," discussing how AI can enhance the efficiency and quality of clinical trials, thereby promoting high-quality development in the industry [1]

医渡科技(02158)发布公告，于2025年9月29日斥资192.71万港元回购33.5万股股份。 ...

格隆汇9月29日丨医渡科技(02158.HK)公告，9月29日耗资192.7万港元回购33.5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年9月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

格隆汇9月26日丨医渡科技(02158.HK)公告，9月26日耗资200万港元回购35.3万股。 ...

医渡科技(02158)发布公告，该公司于2025年9月26日斥资199.92万港元回购35.3万股股份，每股回购价 格为5.57-5.69港元。 ...

智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年9月26日斥资199.92万港元回购35.3万股股 份，每股回购价格为5.57-5.69港元。 ...

FF305 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年9月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | ...

Core Viewpoint - Yidu Technology (2158.HK) shares increased by 5.91% to HKD 6.09 following the announcement of a significant project win in clinical research [1] Group 1: Company Developments - Yidu Technology's affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project amount is approximately CNY 55.82 million [1] - The company utilizes its proprietary core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system, enabling efficient innovation and low-cost scalable applications of AI technology [1] Group 2: Industry Impact - The implementation of AI technology is driving intelligent decision-making across the entire healthcare ecosystem, which includes medicine, pharmaceuticals, insurance, and patients [1]